Barbara Gayle Duncan Halozyme Therapeutics, Inc. (HALO) insider trading activity

Barbara Gayle Duncan is of HALOZYME THERAPEUTICS, INC.. Currently has a direct ownership of 19,919 shares of HALO, which is worth approximately $1.13 Million. The most recent transaction as insider was on May 01, 2025, when has been sold 4,165 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 19.9K

26.44% 3M change

26.44% 12M change

Total Value Held $1.13 Million

Barbara Gayle Duncan Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 01 2025	BUY Grant, award, or other acquisition	-	4,165 Added 17.29%	19,919 Common Stock
Apr 25 2024	BUY Grant, award, or other acquisition	-	6,501 Added 29.21%	15,754 Common Stock
May 05 2023	BUY Grant, award, or other acquisition	-	8,065 Added 46.57%	9,253 Common Stock
Feb 03 2023	BUY Grant, award, or other acquisition	-	1,188 Added 50.0%	1,188 Common Stock

Also insider at

IMMU

IMMUNOMEDICS INC

Director

AVIR

Atea Pharmaceuticals, Inc. Healthcare

FUSN

Fusion Pharmaceuticals Inc. Healthcare

OVID

Ovid Therapeutics Inc. Healthcare

JNCE

Jounce Therapeutics, Inc. Healthcare

Director

ADAP

Adaptimmune Therapeutics PLC Healthcare

Director

BGD